• Equity PC Ratio   0.57
  • |
  • Index PC Ratio   1.14
  • |
  • Total PC Ratio   0.97
  • |
  • VIX PC Ratio   0.54
  • VIX 15.85
  • VXN 20.63
  • VXO 18.01
  • ISEE 85.00

TruCharts Trading Strategies and Stock Buy/Sell Reports
(Show Details)


Chart Settings
No saved settings found!

Chart Type:
From: / / To: / /
Show detail in :
 Chart Skins:      
Price Overlays:





Indicator Windows:





NO
Refresh      
GENE (Genetic Technologies Ltd)
Last Trade 0.6823 Dividend/Share 0 PE Ratio null
Date May 24-2019 Dividend Yield 0.000 Return on Assets -80.22
Change -0.0176 ExDividend Date 0 Return on Capital null
Bid 0 Latest EPS -0.24 Price/Sale 160.826
Ask 0 LatestEPS Date 2018-06-30 Price to Book 5.94
Volume 1180 EPS ttm 0.000 Institutional % 3.4
Avg Volume 2.04M Shares Outstanding 17.63M Insider % null
Open 0.6789 Float 17.63M Short Ratio null
Prev Close 0.6999 Return On Equity -97.93 5 Year Change % -0.872
High 0.6989 Consensus EPS 0 2 Year Change % -0.368
Low 0.6502 No. of Estimate 0.000 1 Year Change % -0.441
52 Week High 2.04 EPS Surprise $ null YTD Change % 0.045
52 Week Low 0.512 EPS Surprise Percent 0 6 Month Change % -0.350
52 Week Change -44.008 EBITDA 0M 3 Month Change % -0.197
50 Day MA 0.86471 Revenue 0M 1 Month Change % -0.157
200 Day MA Gross Profit 0M 5 Day Change % -0.356
Market Cap 12.34M Cash 0M 30 Day Change % -0.158
Beta 3.815633 Debt 0M Stock Exchange NASDAQ Capital Market
Sector Healthcare Revenue Per Share 0 Short Interest 0
Short Date 0 Revenue Per Employee 0 Short Ratio null
Data courtesy of IEX
Company Profile

Genetic Technologies Limited operates as a life science company, specializing in the fields of genetics and genomics primarily in Australia. The company provides genetic testing services to human beings for disease susceptibility, parentage, individual identity, forensics, and sports performance; animals, such as dogs, horses, birds, alpacas, exotics, and zoo animals for parentage, pedigree, traits, and disease susceptibility; and plants for traits and disease susceptibility. It also offers canine reproductive services, as well as involves in licensing its non-coding DNA patents. In addition, the company offers BREVAGen, a diagnostic test that informs clinicians and patients about individual, non-familial, sporadic risk of breast cancer for women where a breast biopsy outcome is indeterminate. The company was formerly known as Duketon Goldfields N.L. and changed its name to Genetic Technologies Limited in August 2000. Genetic Technologies Limited was incorporated in 1987 and is based in Fitzroy, Australia.